Oral Fingolimod May Reduce Disease Activity in Relapsing MS [UPDATE #1]CLICK FOR MORE
[The New England Journal of Medicine 2006;1124-1140, 1088-1091]
"Results of a proof-of-concept randomized trial of fingolimod, an oral immune-modulating drug, show that treatment reduced the number of gadolinium-enhancing lesions on MRI as well as relapse-related clinical end points in patients with relapsing multiple sclerosis (MS).

'Our results show that oral fingolimod may be a treatment option for relapsing multiple sclerosis,' the researchers, with first author Ludwig Kappos, MD, from the University Hospital, Basel, Switzerland, conclude in their report. 'Before these findings can be considered clinically directive, the benefits and risks of fingolimod need to be further evaluated in larger-scale, longer-term clinical studies."